文献速递腹部CT

包含CT特征的评分系统预测可切除胰腺导管腺癌根治性切除后早期复发:一项双中心回顾性研究

A risk score system including CT features for predicting early recurrence of resectable pancreatic ductal adenocarcinoma after radical resection: a dual-center retrospective study.
PubMed 文献 · Eur Radiol · 2025-05-02

本研究基于双中心回顾性数据,纳入可切除胰腺导管腺癌根治性切除患者,利用Cox回归建立包含CA19-9、CT神经周围侵犯、肿瘤坏死及CT淋巴结转移的早期复发评分(ERS),在测试队列和验证队列中其AUC分别为0.851和0.901,均优于AJCC TNM分期。

要点

  • CT显示的神经周围侵犯、淋巴结转移及肿瘤坏死是可切除PDAC早期复发的独立预测因素。
  • ERS在测试队列AUC 0.851、验证队列AUC 0.901,均优于AJCC TNM分期(AUC 0.630和0.534)。
  • ERS高危组术后1年复发率在测试队列为81.4% vs 低危组22.5%,验证队列为81.2% vs 26.7%。

核心结论

  • ERS可无创预测可切除PDAC的早期复发,性能优于AJCC TNM系统。

研究设计与样本

  • 双中心回顾性研究,开发队列210例(平均年龄60±10岁,男129例),测试队列92例(60±9岁,男60例),验证队列31例(62±7岁,男20例);所有CT特征由两名盲法放射科医师独立评估;采用Cox回归分析建立ERS,并与AJCC TNM分期系统比较。

关键影像表现/征象

  • CT显示的神经周围侵犯、淋巴结转移及肿瘤坏死为影像学预测征象。

诊断标准与关键数值

  • ERS组成:CA19-9(HR 1.57,p=0.044)、CT神经周围侵犯(HR 1.83,p=0.037)、肿瘤坏死(HR 3.20,p<0.001)、CT淋巴结转移(HR 1.84,p=0.004)。
  • ERS预测早期复发的AUC在测试队列为0.851,验证队列为0.901;AJCC TNM分期AUC分别为0.630和0.534(p<0.05)。
  • ERS高危组术后1年复发率:测试队列81.4% vs 低危组22.5%(p<0.001);验证队列81.2% vs 26.7%(p=0.003)。

临床应用与阅片要点

  • 阅片时可关注CT上的神经周围侵犯、淋巴结转移及肿瘤坏死征象,结合CA19-9计算ERS以评估早期复发风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To develop a score system including CT features for predicting postoperative early (≤ 1 year) recurrence-free survival (RFS) in resectable pancreatic ductal adenocarcinoma (PDAC) patients who underwent radical resection and assess its performance.

MATERIALS AND METHODS: This dual-center, retrospective study included patients with resectable PDAC who underwent radical resection from September 2016 to April 2023. All CT features were independently evaluated by two blinded radiologists. An early recurrence score (ERS) based on CT and clinical features, for predicting early recurrence risk, was developed by Cox regression analysis in the developing cohort, and was validated in the testing and validation cohorts and compared with AJCC TNM staging system.

RESULTS: This study included 210 patients in the development cohort (mean age ± standard deviation, 60 ± 10 years; 129 men), 92 patients in the testing cohort (60 ± 9 years; 60 men), and 31 patients in the validation cohort (62 ± 7 years; 20 men). CA19-9 (hazard ratio [HR], 1.57; p = 0.044), perineural invasion on CT (HR, 1.83; p = 0.037), tumor necrosis (HR, 3.20; p < 0.001), and lymph nodes metastasis on CT (HR, 1.84; p = 0.004) formed the ERS. Its AUC of 0.851 and 0.901, superior to AJCC TNM staging (AUC of 0.630 and 0.534) in the testing and validation cohorts, (p < 0.05), respectively. The high-risk patients predicted by ERS had significantly higher postoperative 1-year recurrence rates than their low-risk counterparts in both the testing cohort (81.4% vs 22.5%, p < 0.001) and the validation cohort (81.2% vs 26.7%, p = 0.003).

CONCLUSION: The ERS noninvasively predicted early recurrence in resectable PDAC, outperforming the AJCC TNM system.

KEY POINTS: Question More accurately risk-stratifying PDAC patients would allow for better treatment planning. Findings Perineural invasion on CT, lymph nodes metastasis on CT, tumor necrosis, and CA19-9 were associated with early recurrence of resectable PDAC. Clinical relevance The ERS system showed better predictive performance for early recurrence in resectable PDAC and outperformed the American Joint Commission on Cancer TNM system.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Deng Y, Yu H, Zins M, et al. A risk score system including CT features for predicting early recurrence of resectable pancreatic ductal adenocarcinoma after radical resection: a dual-center retrospective study. Eur Radiol. 2025. PMID: 40314786. doi:10.1007/s00330-025-11632-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。